The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo

Journal of Clinical Psychopharmacology

Volumn 23, Issue 2, 2003, Pages 169-175

  Gafni, I ^a   Busto, U E ^b,c,e   Tyndale, R F ^a,c   Kaplan, H L ^c,e   Sellers, Edward M ^a,c,d,e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f Ventana Clinical Research Corporation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYFLUNITRAZEPAM; 5 HYDROXYOMEPRAZOLE; 7 AMINOFLUNITRAZEPAM; BENZODIAZEPINE; CYTOCHROME P450 2C19; DIAZEPAM DERIVATIVE; FLUNITRAZEPAM; NORFLUNITRAZEPAM; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; MALE; NORMAL HUMAN; PREMEDICATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUNITRAZEPAM; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES;

EID: 0037380695     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200304000-00009     Document Type: Article

References (32)

1. Mattila MAK, Larni HM. Flunitrazepam: a review of its pharmacological properties and therapeutic use. Drugs 1980;20:353-74.
2. Woods JH, Winger G. Abuse liability of flunitrazepam. J Clin Psychopharmacol 1997;17:1S-57S.
3. CEWG. Trends in drug abuse: advance report. Fact sheet on Rohypnol. Rockville, MD: National Institute on Drug Abuse Epidemiology, 1995.
4. Saum CA, Inciardi JA. Rohypnol misuse in the United States: substance use and misuse. 1997;32:723-31
5. Arendt RM, Greenblatt DJ, Liebisch DC, et al. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology 1987;93:72-6.
6. Simmons MM, Cupp MJ. Use and abuse of flunitrazepam. Ann Pharmacol 1998;32:117-9.
7. Wickstrom E, Amrein R, Haefelfinger P, et al. Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. Eur J Clin Pharmacol 1980;17:189-96.
8. Singlas E. Pharmacocinetique du flunitrazepam. La Nouvelle Presse Medicale 1979;8:2519-22.
9. Dorow RG, Seidler J, Schneider HH. A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. Br J Clin Pharmacol 1982;13:561-5.
10. Drouet-Coassolo C, Iliadis A, Coassolo P, et al. Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with health volunteers. Fundam Clin Pharmacol 1990;4:643-51.
11. Berthault F, Kintz P, Mangin P. Simultaneous high-performance liquid chromatographic analysis of flunitrazepam and four metabolites in serum. J Chromatogr B 1996;685:383-7.
12. Cano JP, Sumirtapura YC. Pharmacocinetique comparee du diazepam et du flunitrazepam. Ann Anesthesiol Fr 1981;2:175-9.
13. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994;38:131-7.
14. Coller JK, Somogyi AA, Bochner F. Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica 1999;29:973-86.
15. Kilicarslan T, Haining RL, Rettie AE, et al. Flunitrazepam metabolism by cytochromes P450 2C19 and 3A4. Drug Metabol Dispos 2001;29:460-5.
16. Hesse LM, Venkatakrishnan K, vonMoltke LL, et al. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metabol Dispos 2001;29:133-40.
17. deMorais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biologic Chem 1994;269:15419-22.
18. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
19. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-30.
20. Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Therapeutics 1992;51:388-97.
21. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Therapeutics 1989;46:198-207.
22. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Therapeutics 1989;43: 53-76.
23. Chang M, Dahl M-L, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
24. deMorais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
25. Gafni I. The role of cytochrome P450 2C19 in flunitrazepam pharmacokinetics and pharmacodynamics in vivo. Toronto: University of Toronto, Institute of Medical Science, 2001:221.
26. Lagerstrom P-O, Persson B-A. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984;309:347-56.
27. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Therapeutics 1995;57:662-9.
28. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
29. Wan J, Xia H, He N, et al. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 1996;42:471-4.
30. Karam WG, Goldstein JA, Lasker JM, et al. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabol Dispos 1996;24:1081-7.
31. Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Therapeutics 1996;59:647-53.
32. Qin X, Xie H, Wang W, et al. Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Therapeutics 1999;66:642-6.